Francisco J. Esteva
@dresteva.bsky.social
Medical Oncologist specializing in breast cancer research and treatment. Opinions are my own. Not medical advice.
🎥 Start here: trusted cancer info
New videos weekly—subscribe below ⬇️
https://youtu.be/vcetk3Ixiv0?si=70_ooCr-9ytO2G6y
🎥 Start here: trusted cancer info
New videos weekly—subscribe below ⬇️
https://youtu.be/vcetk3Ixiv0?si=70_ooCr-9ytO2G6y
#ASCO25 trials suggest carboplatin may be safely omitted from neoadjuvant therapy in many HER2+ early breast cancers. neoCARHP showed non-inferior pCR without carboplatin and fewer side effects. CompassHER2-pCR confirmed strong THP efficacy, especially in ER− tumors.
#bcsm @ascocancer.bsky.social
#bcsm @ascocancer.bsky.social
June 3, 2025 at 1:43 PM
#ASCO25 trials suggest carboplatin may be safely omitted from neoadjuvant therapy in many HER2+ early breast cancers. neoCARHP showed non-inferior pCR without carboplatin and fewer side effects. CompassHER2-pCR confirmed strong THP efficacy, especially in ER− tumors.
#bcsm @ascocancer.bsky.social
#bcsm @ascocancer.bsky.social
Are serial liquid biopsies finally ready for prime time?
If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.
That means #ctDNA won’t just monitor—it could guide treatment.
@ascocancer.bsky.social
#bcsm
If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.
That means #ctDNA won’t just monitor—it could guide treatment.
@ascocancer.bsky.social
#bcsm
June 1, 2025 at 11:46 PM
Are serial liquid biopsies finally ready for prime time?
If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.
That means #ctDNA won’t just monitor—it could guide treatment.
@ascocancer.bsky.social
#bcsm
If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.
That means #ctDNA won’t just monitor—it could guide treatment.
@ascocancer.bsky.social
#bcsm
New hope for hormone-resistant breast cancer?
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯
@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯
@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
June 1, 2025 at 6:19 PM
New hope for hormone-resistant breast cancer?
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯
@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯
@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
Just returned from #SABCS24—what an incredible experience! It was great reconnecting with old friends, making new connections, and immersing myself in the latest breakthroughs in breast cancer research and treatment. Events like this remind me how collaboration drives progress.
December 15, 2024 at 1:34 PM
Just returned from #SABCS24—what an incredible experience! It was great reconnecting with old friends, making new connections, and immersing myself in the latest breakthroughs in breast cancer research and treatment. Events like this remind me how collaboration drives progress.